Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

HNF1A gene mutations and premature ovarian failure (POF): evidence from a clinical paradigm combining MODY 3 and POF.

Hormones (Athens, Greece)·2024

Same author

Adenomyosis: Disease, uterine aging process leading to symptoms, or both?

Facts, views & vision in ObGyn·2020

Same author

Can pelvic organ prolapse in postmenopausal women be treated with laser therapy?

Climacteric : the journal of the International Menopause Society·2020

Same author

Hysteroscopy for training residents using uterine post-hysterectomy specimens with a mobile hysteroscope.

Facts, views & vision in ObGyn·2020

Same author

Safety of non-steroidal anti-inflammatory drugs in postpartum period in women with hypertensive disorders of pregnancy: systematic review and meta-analysis.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2020

Same author

A study protocol of vaginal laser therapy in gynecological cancer survivors.

Climacteric : the journal of the International Menopause Society·2019

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Published on: September 16, 2021

Pharmacogenetics in ovarian stimulation--current concepts.

D Loutradis¹, A Vlismas, P Drakakis

¹Unit of Reproductive Medicine, "Alexandra" Hospital, 1st Department of Obstetrics and Gynecology, Athens University Medical School, Athens, 175 61, Greece. loutradi@otenet.gr

Annals of the New York Academy of Sciences

|April 30, 2008

Summary

Genetic variations in the follicle-stimulating hormone receptor (FSHR) gene impact ovarian response to FSH stimulation in women undergoing assisted reproduction. Understanding these genetic factors can personalize fertility treatments.

More Related Videos

Fertility Preservation in Patients with Severe Ovarian Dysfunction

Fertility Preservation in Patients with Severe Ovarian Dysfunction

Published on: March 25, 2021

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

Published on: May 9, 2021

Related Experiment Videos

Last Updated: Jul 5, 2026

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Published on: September 16, 2021

Fertility Preservation in Patients with Severe Ovarian Dysfunction

Fertility Preservation in Patients with Severe Ovarian Dysfunction

Published on: March 25, 2021

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

Published on: May 9, 2021

Area of Science:

Reproductive Endocrinology
Human Genetics
Pharmacogenetics

Background:

Ovarian response to follicle-stimulating hormone (FSH) varies significantly among women.
Identifying genetic factors influencing FSH response is crucial for optimizing assisted reproduction techniques (ARTs).

Purpose of the Study:

To investigate the role of genetic variability, specifically in the FSH receptor (FSHR) gene, in modulating ovarian response to FSH stimulation.
To explore the potential of pharmacogenetics in personalizing fertility treatments.

Main Methods:

Analysis of FSHR gene polymorphisms, focusing on Ser680Asn and Thr307Ala variants.
Correlating specific genotypes with ovarian response in women undergoing in vitro fertilization (IVF).

Main Results:

The Ser680Asn polymorphism of the FSHR gene influences ovarian response to FSH.
Women with the Ser/Ser genotype exhibit FSHR that is more resistant to FSH action, potentially affecting treatment outcomes.

Conclusions:

Genetic markers, such as FSHR polymorphisms, can predict ovarian response to FSH stimulation.
Routine genetic testing before ovarian stimulation could enable personalized FSH dosing and reduce treatment complications in ARTs.